ST-2; a Non-invasive Fibrosis Marker for Chronic Hepatitis B

NCT01633554 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2012-07-04

No results posted yet for this study

Summary

IL-33 is a recently identified number of the IL-1 family. Hepatic over-expression of IL-33 has been recently linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33. We aimed to determine ability of ST2 to predict fibrosis in chronic hepatitis B.

Conditions

  • Sequela of Chronic Liver Disease

Sponsors & Collaborators

  • Turkiye Yuksek Ihtisas Education and Research Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-07-31
Completion
2012-09-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01633554 on ClinicalTrials.gov